Aerovate Therapeutics (AVTE) Stock Analysis

What Aerovate Therapeutics does

Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on innovating therapies to enhance the well-being of patients afflicted with rare cardiopulmonary illnesses across the United States. The company's principal effort involves advancing AV-101, an inhaled dry powder variant of imatinib, which is currently undergoing a Phase 2b/Phase 3 clinical study for the management of pulmonary arterial hypertension. Established in 2018, Aerovate Therapeutics, Inc. maintains its corporate headquarters in Waltham, Massachusetts.

Key metrics

ETFs linked to AVTE

Broad-market and Healthcare sector ETFs an investor holding Aerovate Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how AVTE fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Aerovate Therapeutics?

Aerovate Therapeutics trades under the ticker AVTE on NASDAQ.

Which exchange is AVTE listed on?

AVTE is listed on NASDAQ.

What sector does Aerovate Therapeutics operate in?

Aerovate Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze AVTE in a portfolio?

PortView shows AVTE's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.